header logo image


Page 153«..1020..152153154155..160170..»

How one woman took control of her rare disease and achieved her dream – Times of Oman

July 25th, 2022 2:00 am

Natalie Metzger is living a life that once seemed impossible. At only 35 years old, she's already an award-winning director, writer and producer. She travels extensively, and her films have premiered at top festivals around the world including Sundance, Cannes and more. Being a filmmaker was an ambitious goal, but it wasn't until Natalie took charge of her life behind the camera and became an advocate for her health that pursuing this Hollywood dream was even an option.

Rare and potentially fatal

Natalie lives with a very rare and potentially life-threatening genetic condition called hereditary angioedema, or HAE. It causes unpredictable episodes of uncontrolled and often severe swelling that can impact areas of the body such as the hands, feet, stomach, face and even the throat, which can be fatal.

Natalie's father has HAE, which meant she had a 50-50 chance of inheriting the disease. When she began having symptoms at the age of 17, her parents' fear was confirmed - she, too, had HAE.

HAE swelling can last for days, and attacks can happen multiple times per month, impacting the ability to participate in everyday activities such as school, work and social events. Natalie's attacks worsened as she went to college, and HAE began taking a significant toll on her life.

"I was having an attack every couple of weeks," said Natalie. "I was in and out of the hospital all of the time."

While HAE episodes can occur for seemingly no reason, common triggers include physical injury, as well as Natalie's most frequent cause of attacks - stress. Since stress comes with filmmaking and extensive travel is also required - often daunting for those with HAE given the need to be near a hospital knowledgeable of and able to treat HAE in case of a severe attack - Natalie thought that she might not be able to pursue it as a career.

But, determined to live the life she wanted to live, Natalie began taking a proactive approach to managing her HAE. And things began to change.

A proactive approach

HAE can be treated in two ways. Acute medication is used to lessen symptoms when an attack is imminent or underway. And preventative medication is taken on an ongoing basis to help prevent HAE attacks and minimize their severity. Because HAE is a lifelong disease, preventing attacks can be a key part of regaining a sense of normalcy.

For Natalie, finding the right prophylactic treatment has made all the difference. Her swelling attacks are now well controlled, and if she has occasional breakthrough swelling, it's generally mild.

"When I was in college and considering what I was going to be doing with my life, I wasn't sure I'd be able to handle the demands of film because of my HAE, but on demand and preventative medications have been life changing," said Natalie. "They've really allowed me to have the career of my dreams - I'm able to make movies and go all around the world for film productions and festivals. I don't think I would be able to be a filmmaker if I didn't have my medication."

Treatment advances for HAE have come a long way in recent years and include medications that are taken in different ways, requiring varying levels of skill and time commitment to administer, giving those with HAE more options for finding the right treatment plan that fits their unique needs and lifestyle.

"We talk a lot about the burden of the condition, but the burden of treatment is something we've become more aware of as options have advanced," said Marc A. Riedl, MD, Clinical Director, US HAEA Angioedema Center. "When designing a treatment plan, patients should be open with their medical team about both their treatment goals and how treatment fits into their lifestyle. We're now reaching a point where people with HAE are often able to do the things they want in life without HAE or their treatments interfering."

While many with HAE have learned to tolerate difficult or inconvenient aspects of their treatment or may be afraid to "rock the boat" by trying a new treatment option, Natalie's experience shows that investing the time to find the right approach can be life changing.

"I've tried all of the preventative treatments over the years - intravenous, subcutaneous, and oral," said Natalie. "They're getting easier and easier to use and less invasive on my day-to-day life. It's amazing to think how far I've come personally and how far we've evolved in the HAE space."

Important advice for those facing health challenges

Given all that Natalie has been through, she has a few pieces of advice for anyone navigating the challenges of a condition like HAE:

1. Assess what YOU really want: Think about your goals. Consider your lifestyle, what factors are most important to you, the impact of the disease on your life and how treatment fits into it.

2. Have a plan: Preparation is key, especially when living with a chronic condition. Whether jotting down notes in advance of a doctor's appointment or ensuring you travel with the necessary medication, having a plan is essential to success.

3. Go for it: Be open and honest with your medical team. Have an empowered conversation about your goals in treatment and life. You should have a shared voice in your treatment decision-making process - studies show it leads to better outcomes.

Natalie recently got married and is looking ahead to what life and her busy career have in store for her next.

"Through my work, I'm able to pursue another passion - raising awareness of HAE and highlighting the stories of people impacted by this rare disease, as I did in the documentary 'Special Blood,'" she said. "I will continue to advocate for those with HAE to take charge of their health and pursue their own dreams while I live out mine." -BPT

Read more here:
How one woman took control of her rare disease and achieved her dream - Times of Oman

Read More...

Felix Biotechnology Awarded Competitive Grant from the National Institutes of Health to Power Phage Engineering Platform – PR Newswire

July 17th, 2022 1:48 am

Felix awarded competitive NIH grant to build a microfluidics platform which will accelerate generalizable phage therapy.

Bacteriophage, or phage, are natural predators of bacteria with enormous potential to treat bacterial infections, but most only kill a narrow range of bacteria which limits their clinical potential. To reach the clinic, Felix is engineering phage to kill a broader range of bacteria, and this requires large amounts of data on phage-bacteria interactions. Supported by this SBIR grant, Felix will develop new tools that accelerate the acquisition of this critical phage-bacteria interaction data.

"We are excited to apply the high throughput tools that have been developed in the microfluidics space to address the constraints that limit phage data collection," said UCSF professor Adam Abate, world-renowned microfluidics expert and collaborator on this project. Professor Abate continues, "With microfluidics we can generate the large amount of data needed to leverage the power of machine learning approaches to identify how to engineer viruses to kill a broader range of bacteria."

"Phage therapy has been around for a long time but has not reached its potential due to the narrow host ranges of most therapeutic phages. The tools being developed in this grant will allow us to overcome this key technical limitation and develop generalizable phage therapy to effectively treat antimicrobial resistant infections and save lives," said Rob McBride, co-founder of Felix.

As the incidence of deadly antimicrobial infections increases globally, Felix remains at the forefront of global efforts to create novel and effective solutions. Felix thanks the NIH and other funders for their generous support and efforts to shape a better future for global health.

About Felix Biotechnology

Felix Biotechnology is focused on discovering, developing and deploying customizable antimicrobials targeting urgent microbial threats. Felix's discovery and engineering technology platforms, built on technology from Yale University and Lawrence Berkeley National Laboratory, generate solutions that overcome the key limitations of traditional antimicrobials to kill targeted bacteria while preserving healthy microbiome function. Felix is a seed stage company funded by multiple investors, including Y Combinator, Illumina Accelerator and Point72 Ventures. More information is available at http://www.felixbt.com.

For more on Felix Biotechnology, please visit: https://www.felixbt.com/

For more on the Adam Abate lab, please visit https://www.abatelab.org/

For more on the National Science Foundation's Small Business Programs, please visit: https://seedfund.nsf.gov/

SOURCE Felix Biotechnology, Inc.

Original post:
Felix Biotechnology Awarded Competitive Grant from the National Institutes of Health to Power Phage Engineering Platform - PR Newswire

Read More...

$11.8 Billion Worldwide Bioreactor Industry to 2027 – Featuring Sartorius, Solaris Biotechnology and Thermo Fisher Scientific Among Others -…

July 17th, 2022 1:48 am

DUBLIN--(BUSINESS WIRE)--Jul 15, 2022--

Javascript is required for you to be able to read premium content. Please enable it in your browser settings.

kAm%96 8=@32= 3:@C624E@C >2C<6E C624965 2 G2=F6 @7 &$S d]ec q:==:@? :? a_a`] {@@<:?8 7@CH2C5[ E96 AF3=:D96C 6IA64ED E96 >2C<6E E@ C6249 2 G2=F6 @7 &$S ``]gc q:==:@? 3J a_af[ 6I9:3:E:?8 2 rpv# @7 `b]`eT 5FC:?8 a_a`a_af]k^Am

kAmr@>A2?:6D |6?E:@?65k^Am

kF=mk=:ma>28 pvk^=:mk=:m33:3:@E649 v>3wk^=:mk=:mq:@6?8:?66C:?8 pvk^=:mk=:mtAA6?5@C7 $tk^=:mk=:mv6E:?86 pqk^=:mk=:mx?7@CD pvk^=:mk=:m|6C4< zv2pk^=:mk=:m!2== r@CA@C2E:@? Ws2?296C r@CA@C2E:@?Xk^=:mk=:m$2CE@C:FD pvk^=:mk=:m$@=2C:D q:@E649?@=@8J $C=k^=:mk=:m%96C>@ u:D96C $4:6?E:7:4 x?4]k^=:mk^F=m

kAmz66A:?8 😕 >:?5 E96 F?46CE2:?E:6D @7 r~'xs`h[ H6 2C6 4@?E:?F@FD=J EC24<:?8 2?5 6G2=F2E:?8 E96 5:C64E 2D H6== 2D E96 :?5:C64E :?7=F6?46 @7 E96 A2?56>:4 @? 5:776C6?E 6?5 FD6 D64E@CD] %96D6 :?D:89ED 2C6 :?4=F565 😕 E96 C6A@CE 2D 2 >2;@C >2C<6E 4@?EC:3FE@C]k^Am

kAmp 3:@C624E@C C676CD E@ 2 76C>6?E2E:@? G6DD6=[ H96C6:? 3:@=@8:42= C624E:@?D 2C6 6I64FE65 7@C 56G6=@A:?8 6?KJ>6D 2?5 G2C:@FD @C82?:D>D[ :?4=F5:?8 324E6C:2[ 2?:>2= 46==D 2?5 J62DE[ F?56C 4@?EC@==65 4@?5:E:@?D] xE 2:5D 😕 AC@5F4:?8 D6G6C2= A92C>246FE:42=D[ DF49 2D G244:?6D 2?5 >@?@4=@?2= 2?E:3@5:6D[ >2:?E2:?:?8 E96 :?9@>@86?6@FD DE2E6 @7 E96 46==D E@ @3E2:? E96 56D:C65 @FEAFE[ 2?5 >@?:E@C:?8 E96 6?G:C@?>6?E2= 4@?5:E:@?D 7@C AC@>@E:?8 E96 46== 7@C>2E:@? AC@46DD]k^Am

kAm~? 244@F?E @7 E96D6 AC@A6CE:6D[ 2 3:@C624E@C 😀 6IE6?D:G6=J FD65 3J 3:@A92C>246FE:42= 4@>A2?:6D[ C6D62C49 2?5 56G6=@A>6?E W#U2>AjsX :?DE:EFE:@?D[ 2?5 4@?EC24E C6D62C49 @C82?:K2E:@?D Wr#~DX] pE AC6D6?E[ :E 😀 4@>>6C4:2==J 2G2:=23=6 😕 8=2DD[ DE2:?=6DD DE66=[ 2?5 D:?8=6FD6 >2E6C:2= EJA6D]k^Am

kAm%96 8=@32= 3:@C624E@C >2C<6E :D >2;@C=J 5C:G6? 3J E96 :?4C62D:?8 AC6G2=6?46 @7 G2C:@FD 49C@?:4 5:D62D6D[ DF49 2D 42?46C 2?5 5:236E6D[ 6DA64:2==J 2>@?8DE E96 DE625:=J C:D:?8 86C:2EC:4 A@AF=2E:@?]k^Am

kAmx? =:?6 H:E9 E9:D[ E96 8C@H:?8 ?665 7@C AC6G6?E:G6 G244:?6D[ A2CE:4F=2C=J 5FC:?8 E96 DF556? @FE3C62< @7 E96 4@C@?2G:CFD 5:D62D6 Wr~'xs`hX A2?56>:4[ 92G6 AC@>AE65 D6G6C2= A92C>246FE:42= 4@>A2?:6D E@ 4@?D:56C23=J :?G6DE 😕 C6D62C49 2?5 56G6=@A>6?E W#U2>AjsX 24E:G:E:6D E@ 6IE6?5 E96:C AC@5F4E:@? 42A24:E:6D] %9:D[ 😕 EFC?[ 😀 :?7=2E:?8 E96 @G6C2== D2=6D @7 3:@C624E@CD 24C@DD E96 8=@36]k^Am

kAmp55:E:@?2==J[ D:8?:7:42?E E649?@=@8:42= 25G2?46>6?ED[ DF49 2D E96 :?EC@5F4E:@? @7 D:?8=6FD6 3:@C624E@CD W$&qDX 7@C @AE:>:K:?8 E96 BF2=:EJ[ 7=6I:3:=:EJ[ 2?5 D42=23:=:EJ @7 >:4C@@C82?:D>DV 7@C>2E:@? @A6C2E:@?D H:E9 >:?:>2= 4@DE 2?5 6?6C8J C6BF:C6>6?ED[ 2C6 A@D:E:G6=J DE:>F=2E:?8 E96 >2C<6E 8C@HE9]k^Am

kAmpA2CE 7C@> E9:D[ :?4C62D:?8 3:@A92C>246FE:42=D >2?F724EFC:?8 42A24:E:6D 24C@DD 56G6=@A:?8 ?2E:@?D[ 2=@?8 H:E9 E96 C:D:?8 56>2?5 7@C 3:@C624E@CD E92E DFAA@CE >@56C?[ 6G@=G:?8[ 9:8946== 56?D:EJ[ 2?5 :?E6?D:7:65 4=:?:42= AC@46DD6D C6BF:C:?8 9:89 @IJ86? EC2?D76C 2?5 8C62E 42C3@? 5:@I:56 Wr~aX C6>@G2= 2C6 AC@A6==:?8 E96 >2C<6E 8C@HE9]k^Am

kAm~E96C 724E@CD[ DF49 2D C2A:5 6IA2?D:@? 😕 E96 A92C>246FE:42= 2?5 3:@=@8:4D D64E@CD[ E96 6D42=2E:?8 ?665 7@C 67764E:G6 EC62E>6?E 5CF8D[ 2?5 E96 :?4C62D:?8 2H2C6?6DD 2>@?8 4@?DF>6CD C682C5:?8 E96 7@C>F=2E:@? 2?5 2G2:=23:=:EJ @7 A6CD@?2=:K65 >65:4:?6D[ 2C6 4@?EC:3FE:?8 E@ E96 >2C<6E 8C@HE9 D:8?:7:42?E=J]k^Am

kAmz6J "F6DE:@?D p?DH6C65 😕 %9:D #6A@CEik^Am

kF=mk=:mw@H 92D E96 8=@32= 3:@C624E@C >2C<6E A6C7@C>65 D@ 72C 2?5 9@H H:== :E A6C7@C> 😕 E96 4@>:?8 J62CDnk^=:mk=:m(92E 92D 366? E96 :>A24E @7 r~'xs`h @? E96 8=@32= 3:@C624E@C >2C<6Enk^=:mk=:m(92E 2C6 E96 <6J C68:@?2= >2C<6EDnk^=:mk=:m(92E :D E96 3C622C<6E 32D65 @? E96 EJA6nk^=:mk=:m(92E :D E96 3C622C<6E 32D65 @? E96 FD286nk^=:mk=:m(92E :D E96 3C622C<6E 32D65 @? E96 D42=6nk^=:mk=:m(92E :D E96 3C622C<6E 32D65 @? E96 4@?EC@= EJA6nk^=:mk=:m(92E 2C6 E96 G2C:@FD DE286D :? E96 G2=F6 492:? @7 E96 :?5FDECJnk^=:mk=:m(92E 2C6 E96 <6J 5C:G:?8 724E@CD 2?5 492==6?86D :? E96 :?5FDECJnk^=:mk=:m(92E :D E96 DECF4EFC6 @7 E96 8=@32= 3:@C624E@C >2C<6E 2?5 H9@ 2C6 E96 <6J A=2J6CDnk^=:mk=:m(92E :D E96 568C66 @7 4@>A6E:E:@? 😕 E96 :?5FDECJnk^=:mk^F=m

kAmz6J %@A:4D r@G6C65ik^Am

kAm` !C67246k^Am

kAma $4@A6 2?5 |6E9@5@=@8Jk^Am

kAmb tI64FE:G6 $F>>2CJk^Am

kAmc x?EC@5F4E:@?k^Am

kAmc]` ~G6CG:6Hk^Am

kAmc]a z6J x?5FDECJ %C6?5Dk^Am

kAmd v=@32= q:@C624E@C |2C<6Ek^Am

kAmd]` |2C<6E ~G6CG:6Hk^Am

kAmd]a |2C<6E !6C7@C>2?46k^Am

kAmd]b x>A24E @7 r~'xs`hk^Am

kAmd]c |2C<6E u@C642DEk^Am

kAme |2C<6E qC62

kAmf |2C<6E qC62

kAmg |2C<6E qC62

kAmh |2C<6E qC62

kAm`_ |2C<6E qC62

kAm`` $(~% p?2=JD:Dk^Am

kAm`a '2=F6 r92:? p?2=JD:Dk^Am

kAm`b !@CE6CD u:G6 u@C46D p?2=JD:Dk^Am

kAm`c !C:46 p?2=JD:Dk^Am

kAm`d r@>A6E:E:G6 {2?5D42A6k^Am

kAm`d]` |2C<6E $ECF4EFC6k^Am

kAm`d]a z6J !=2J6CDk^Am

kAm`d]b !C@7:=6D @7 z6J !=2J6CDk^Am

kAmu@C >@C6 :?7@C>2E:@? 23@FE E9:D C6A@CE G:D:E k2 9C67lQ9EEADi^^HHH]C6D62C492?5>2C<6ED]4@>^C6A@CED^de`d_ee^3:@C624E@C>2C<6E8=@32=:?5FDECJEC6?5DD92C6nFE>0D@FC46lq(U2>AjFE>0>65:F>l!C6DD#6=62D6U2>AjFE>04@56lH>A>gCU2>AjFE>042>A2:8?l`faee_`ZZTac``]gZq:==:@?Z(@C=5H:56Zq:@C624E@CZx?5FDECJZE@Za_afZZu62EFC:?8Z$2CE@C:FDTa4Z$@=2C:DZq:@E649?@=@8JZ2?5Z%96C>@Zu:D96CZ$4:6?E:7:4Zp>@?8Z~E96CDU2>AjFE>06I64l;2>FafbAC5Q C6=lQ?@7@==@HQ D92A6lQC64EQm9EEADi^^HHH]C6D62C492?5>2C<6ED]4@>^C^hKbC?6k^2mk^Am

kAm':6H D@FC46 G6CD:@? @? k2 9C67lQ9EEAi^^3FD:?6DDH:C6]4@>Qm3FD:?6DDH:C6]4@>k^2mik2 9C67lQ9EEADi^^HHH]3FD:?6DDH:C6]4@>^?6HD^9@>6^a_aa_f`d__d`de^6?^Q C6=lQ?@7@==@HQm9EEADi^^HHH]3FD:?6DDH:C6]4@>^?6HD^9@>6^a_aa_f`d__d`de^6?^k^2mk^Am

kAmr~}%pr%i k2 9C67lQ9EEAi^^#6D62C49p?5|2C<6ED]4@>Qm#6D62C49p?5|2C<6ED]4@>k^2mk^Am

kAm{2FC2 (@@5[ $6?:@C !C6DD |2?286Ck^Am

kAmk2 9C67lQ>2:=E@iAC6DDoC6D62C492?5>2C<6ED]4@>QmAC6DDoC6D62C492?5>2C<6ED]4@>k^2mk^Am

kAmu@C t]$]% ~77:46 w@FCD r2== `h`fb___cf_k^Am

kAmu@C &]$]^rp} %@== uC66 r2== `g__daegeb_k^Am

kAmu@C v|% ~77:46 w@FCD r2== Zbdb`c`egh__k^Am

kAmzt*(~#sik^Am

kAmx}s&$%#* zt*(~#si wtp{%w qx~%trw}~{~v*k^Am

kAm$~&#rti #6D62C49 2?5 |2C<6EDk^Am

kAmr@AJC:89E qFD:?6DD (:C6 a_aa]k^Am

kAm!&qi _f^`d^a_aa _cidg p|^sx$ri _f^`d^a_aa _cidg p|k^Am

kAmk2 9C67lQ9EEAi^^HHH]3FD:?6DDH:C6]4@>^?6HD^9@>6^a_aa_f`d__d`de^6?Qm9EEAi^^HHH]3FD:?6DDH:C6]4@>^?6HD^9@>6^a_aa_f`d__d`de^6?k^2mk^Am

View post:
$11.8 Billion Worldwide Bioreactor Industry to 2027 - Featuring Sartorius, Solaris Biotechnology and Thermo Fisher Scientific Among Others -...

Read More...

T-cell Lymphoma Market worth $2.89 billion by 2030 – Exclusive Report by InsightAce Analytic – PR Newswire UK

July 17th, 2022 1:47 am

JERSEY CITY, N.J., July 12, 2022 /PRNewswire/ -- InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global T-cell Lymphoma MarketBy Lymphoma Type (Peripheral T-Cell Lymphoma (Cutaneous T-Cell Lymphoma, Anaplastic Large Cell Lymphoma, Angio-Immuno-Blastic T-Cell Lymphoma, And Others (Intestinal T-Cell Lymphoma, Follicular T-Cell Lymphoma)) And T-Cell Lymphoblastic Lymphoma), Therapy (Radiotherapy, Chemotherapy, Immunotherapy, Stem Cell Transplantation, And Others (Antiviral Treatment, Etc.)- Trends, Industry Competition Analysis, Revenue and Forecast To 2030."

According to the latest research by InsightAce Analytic, the global T-cell lymphoma market is valued at US$ 1.44 billion in 2021, and it is expected to reach US$ 2.89 billion by 2030, with a CAGR of 8.4% during the forecast period of 2022-2030.

Request for Sample Pages: https://www.insightaceanalytic.com/request-sample/1312

Lymphoma is a type of blood cancer that develops in the lymphatic system. The body has two prominent lymphocytes that can develop into lymphomas: B-lymphocytes and T-lymphocytes (T-cells). Recent research has shown that malignant T cells control the inflammatory environment, inhibit anti-tumor responses and cellular immunity and form a chronic inflammatory microenvironment that promotes its expansion.

The growth of the T-cell lymphoma market can be attributed to factors such as the rising prevalence of cancer and autoimmune diseases, the growing elderly population, surge in lymphoma cancer incidence due to radiation. Increasing innovations of T-cell lymphoma targeted therapies, growing awareness among the people regarding T-cell Lymphoma and treatments, rising healthcare expenditure, and increasing R&D activities to develop effective T-cell lymphoma-specific therapies are further expected to drive the market growth. The rising incidence of lymphoma cases has encouraged pharmaceutical companies and researchers to invest more in discovering advanced cancer therapies. For instance, Bristol-Myers Squibb (U.S.) got FDA clearance for Istodax (romidepsin), a histone deacetylase (HDAC) inhibitor, as monotherapy for the treatment of peripheral T-cell lymphoma (PTCL) in adults who have undergone at least one previous therapy. Thus, the increasing R&D activities are projected to offer new opportunities for the growth of the T-cell lymphoma market in the forthcoming years.

However, the high cost of T-cell lymphoma therapies, the complex manufacturing processes, and some side effects associated with these therapies are estimated to inhibit market augmentation over the forecast years.

The Asia Pacific region is projected to witness significant growth during the forecast period (2022-2030) due to the increasing research funding, rising prevalence of cancer, and the fast adoption of next-generation therapy techniques.

Enquiry Before Buying: https://www.insightaceanalytic.com/enquiry-before-buying/1312

Major market players operating in the T-cell lymphoma market include4SC AG, Acrotech Biopharma, Affimed, Bausch Health Companies Inc., Biocryst Pharmaceuticals Inc., Bristol-Myers Squibb Company, Chipscreen Biosciences, Citius Pharma, CSPC, CStone Pharmaceuticals, Daiichi-Sankyo, Dizal Pharma, Eisai, Elorac, F. Hoffmann-La Roche Ltd, Genmab A/S, Genor Biopharma, GlaxoSmithKline plc., Innate Pharma, Johnson and Johnson Private Limited, Kyowa Kirin Co., Ltd., Merck and Co. Inc., Novartis AG, Pfizer, Seagen Inc., Secura Bio, Shanghai Junshi Bio, SHIONOGI & Co., Ltd., Solasia, Spectrum Pharmaceuticals Inc., Takeda, Viracta, and Other Prominent Players.

Key developments in the market:

Market Segments

Global T-cell Lymphoma Market, by Lymphoma Type, 2022-2030 (Value US$ Mn)

Global T-cell Lymphoma Market, by Therapy, 2022-2030 (Value US$ Mn)

Global T-cell Lymphoma Market, by Region, 2022-2030 (Value US$ Mn)

North America T-cell Lymphoma Market, by Country, 2022-2030 (Value US$ Mn)

Europe T-cell Lymphoma Market, by Country, 2022-2030 (Value US$ Mn)

Asia Pacific T-cell Lymphoma Market, by Country, 2022-2030 (Value US$ Mn)

Latin America T-cell Lymphoma Market, by Country, 2022-2030 (Value US$ Mn)

Middle East & Africa T-cell Lymphoma Market, by Country, 2022-2030 (Value US$ Mn)

Why should buy this report:

For More Customization @ https://www.insightaceanalytic.com/customisation/1312

Other Related Reports Published by InsightAce Analytic:

Global Regulatory T-Cell (Tregs) Therapies Market

Global Multiple Cancer Monoclonal Antibodies Market

Global CAR T-Cell Therapy For Multiple Myeloma Market

Global Immuno-Oncology Cell Therapy Market

Global Novel T-Cell Immunotherapies Market

About Us:

InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact Us:

InsightAce Analytic Pvt. Ltd.Tel.: +1 551 226 6109Email:info@insightaceanalytic.comSite Visit:www.insightaceanalytic.comFollow Us on LinkedIn @bit.ly/2tBXsgSFollow Us OnFacebook@bit.ly/2H9jnDZ

Logo: https://mma.prnewswire.com/media/1729637/InsightAce_Analytic_Logo.jpg

SOURCE InsightAce Analytic Pvt. Ltd.

Read more here:
T-cell Lymphoma Market worth $2.89 billion by 2030 - Exclusive Report by InsightAce Analytic - PR Newswire UK

Read More...

Cataract Treatment Market Trends, Drivers and Growth Projection Up to 2029 Alcon Vision LLC, Essilor, Ziemer Ophthalmic Systems, Bausch Health,…

July 17th, 2022 1:47 am

Data Bridge Market Research analyses that thecataract treatment marketwill exhibit a CAGR of around 5.00% for the forecast period of 2022-2029. Growing demand for targeted mode of therapies, surge in the research and development activities for the development of noveldrugsand therapies, increasing programmes by government and non-profit organizations to reduce the burden of cataract-related diseases worldwide and increased expenditure for the development ofhealthcareinfrastructure are the major factors attributable to the growth of cataract treatment market.

Cataract is an eye related disorder wherein one suffers blurry vision due to clouding of lens in the eye. Cataract slowly leads to decrease in the vision ability and in some cases even loss of vision. In this medical condition, the protein, that form the lens of an eye get clumped down.

Get a Sample PDF of the report https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-cataract-treatment-market

This cataract treatment market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on cataract treatment market contact Data Bridge Market Research for anAnalyst Brief,our team will help you take an informed market decision to achieve market growth.

Global Cataract Treatment Market Scope and Market Size

The cataract treatment market is segmented on the basis of type, treatment, drugs class, drugs, route of administration, distribution channel and end user. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

To Gain More Insights into the Market Analysis, Browse Summary of the Research [emailprotected] https://www.databridgemarketresearch.com/reports/global-cataract-treatment-market

Cataract Treatment Market Country Level Analysis

The cataract treatment market is analysed and market size insights and trends are provided by country, type, treatment, drugs class, drugs, route of administration, distribution channel and end user as referenced above. The countries covered in the cataract treatment market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).

North America dominates the cataract treatment market owing to the earliest adoption of innovative technologies, growing research and development capacities and well-structured regulatory framework. Asia-Pacific is projected to undergo substantial gains during the forecast period and score the highest CAGR. This is because of the rising expenditure to develop healthcare infrastructure, increasing health care spending, rising prevalence of cataract disorders, favourable regulations and increasing personal disposable income.

The country section of the cataract treatment market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and Cataract Treatment Market Share Analysis

The cataract treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies focus related to cataract treatment market.

The major players operating in the cataract treatment market report are Abbott, Johnson & Johnson Services, Inc, Novartis AG, HOYA Corporation, Carl-Zeiss-Stiftung, Alcon Vision LLC, Essilor, Ziemer Ophthalmic Systems, Bausch Health, GENZUM LIFE SCIENCES, AbbVie Inc, Santen Pharmaceutical Co., Ltd, Omeros Corporation, Sun Pharmaceutical Industries Ltd, EyePoint Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Acumen BioPharma, LLC, Takeda Pharmaceutical Company Limited, AstraZeneca and F. Hoffmann-La Roche Ltd among others.

Browse the complete table of contents at https://www.databridgemarketresearch.com/toc/?dbmr=global-cataract-treatment-market

Related Reports:

Allogenic Stem Cell Therapy Market Size, Shares, Trends and Industry Growth Outlook https://www.databridgemarketresearch.com/reports/global-allogenic-stem-cell-therapy-market

Cancer Stem Cell Therapy Market Size, Shares, Trends and Industry Growth Outlook https://www.databridgemarketresearch.com/reports/global-cancer-stem-cell-therapy-market

North America Stem Cell Therapy Market Size, Shares, Trends and Industry Growth Outlook https://www.databridgemarketresearch.com/reports/north-america-stem-cell-therapy-market

Europe Stem Cell Therapy Market Size, Shares, Trends and Industry Growth Outlook https://www.databridgemarketresearch.com/reports/europe-stem-cell-therapy-market

Asia-Pacific Stem Cell Therapy Market Size, Shares, Trends and Industry Growth Outlook https://www.databridgemarketresearch.com/reports/asia-pacific-stem-cell-therapy-market

Middle East and Africa Stem Cell Therapy Market Size, Shares, Trends and Industry Growth Outlook https://www.databridgemarketresearch.com/reports/middle-east-and-africa-stem-cell-therapy-market

Asia-Pacific Drug-Device Combination Market Size, Shares, Trends and Industry Growth Outlook https://www.databridgemarketresearch.com/reports/global-drug-device-combination-market

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today! Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact Us:-

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:-[emailprotected]

View original post here:
Cataract Treatment Market Trends, Drivers and Growth Projection Up to 2029 Alcon Vision LLC, Essilor, Ziemer Ophthalmic Systems, Bausch Health,...

Read More...

Global Hunter Syndrome Treatment Market Analysis to 2026 – Focus on Hematopoietic Stem Cell Transplant (HSCT) and Enzyme Replacement Therapy (ERT) -…

July 17th, 2022 1:47 am

DUBLIN--(BUSINESS WIRE)--The "Hunter Syndrome Treatment Market Analysis by Treatment (Hematopoietic Stem Cell Transplant (HSCT), Enzyme Replacement Therapy (ERT)), and by Region - Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.

The global hunter syndrome treatment market size is estimated to be USD 995.71 million in 2021 and is expected to witness a CAGR of 7.83% during the forecast period.

Increase in number of patients suffering from hunter syndrome is a key driver for the growth of the global hunter syndrome treatment market.

Additionally, the rise in initiatives taken up by the governments, introduction of novel therapies in the market, and occurrence of strong pipeline portfolio are some of the other drivers propelling the market growth.

Nevertheless, the increasing cost of treatment and lack of awareness about hunter syndrome treatment are expected to restrain the global market growth.

The hunter syndrome treatment market report is categorized into the following segments and subsegments:

By Treatment (Revenue, USD Million, 2021-2029)

By Region (Revenue, USD Million, 2021-2029)

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/gtd8tm

The rest is here:
Global Hunter Syndrome Treatment Market Analysis to 2026 - Focus on Hematopoietic Stem Cell Transplant (HSCT) and Enzyme Replacement Therapy (ERT) -...

Read More...

Singleron supports Project Maleth’s second mission MALETH II by analyzing biological samples sent to space

July 17th, 2022 1:46 am

COLOGNE, Germany, July 14, 2022 (GLOBE NEWSWIRE) -- Maleth Program is the first space bioscience project led by Professor Joseph Borg of the University of Malta. The second mission under the Maleth Program, or Maleth II, was launched on the July 15th, 2022.

Visit link:
Singleron supports Project Maleth’s second mission MALETH II by analyzing biological samples sent to space

Read More...

Bone Therapeutics optimizes statistical analysis and introduces interim analysis in the ongoing ALLOB Phase IIb study for high-risk tibial fractures

July 17th, 2022 1:46 am

PRESS RELEASE - INSIDE INFORMATION

Read more here:
Bone Therapeutics optimizes statistical analysis and introduces interim analysis in the ongoing ALLOB Phase IIb study for high-risk tibial fractures

Read More...

Novozymes plan to further increase prices across the portfolio in response to the significant and persistent hike in incoming cost

July 17th, 2022 1:46 am

Novozymes has experienced unprecedented cost-inflation on raw materials, energy, and logistics. To recover these headwinds, substantial price increases will be implemented.

More:
Novozymes plan to further increase prices across the portfolio in response to the significant and persistent hike in incoming cost

Read More...

Orion Corporation’s financial reporting and Annual General Meeting in 2023

July 17th, 2022 1:46 am

ORION CORPORATION STOCK EXCHANGE RELEASE – FINANCIAL CALENDAR     15 JULY 2022 at 11.00 EEST

Read more:
Orion Corporation's financial reporting and Annual General Meeting in 2023

Read More...

HUTCHMED Initiates Phase I Trial of Anti-CD47 Monoclonal Antibody HMPL-A83 in Patients with Advanced Malignant Neoplasms in China

July 17th, 2022 1:46 am

HMPL-A83 is the thirteenth innovative oncology drug candidate discovered in-house by HUTCHMED and its second large molecule drug candidate to enter clinical studies HMPL-A83 is the thirteenth innovative oncology drug candidate discovered in-house by HUTCHMED and its second large molecule drug candidate to enter clinical studies

Read the original:
HUTCHMED Initiates Phase I Trial of Anti-CD47 Monoclonal Antibody HMPL-A83 in Patients with Advanced Malignant Neoplasms in China

Read More...

Orion Group Half-Year Financial Report 1–6/2022

July 17th, 2022 1:46 am

ORION CORPORATION        HALF-YEAR FINANCIAL REPORT 1–6/2022        15 JULY 2022 at 12:00 EEST

Read the original post:
Orion Group Half-Year Financial Report 1–6/2022

Read More...

SpringWorks Therapeutics Appoints Carlos Albán to its Board of Directors

July 17th, 2022 1:46 am

STAMFORD, Conn., July 15, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced the appointment of Carlos Albán to the Company’s Board of Directors. Mr. Albán, who served as Vice Chairman and Chief Commercial Officer at AbbVie, Inc. (“AbbVie”) until his retirement last year, brings over 30 years of experience in global commercial strategy and operations.

Read the original:
SpringWorks Therapeutics Appoints Carlos Albán to its Board of Directors

Read More...

Kamada Announces Resolution to the Labor Strike at the Company’s Manufacturing Facility in Israel; A New, Eight-Year Collective Agreement Signed

July 17th, 2022 1:46 am

REHOVOT, Israel, July 15, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (Nasdaq: KMDA) (KMDA.TA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, announced today that the Company, the Employees’ Union of Kamada’s Beit Kama production facility in Israel, and the Histadrut - General Federation of Labor in Israel, signed a new collective agreement detailing the understandings reached between the parties. The agreement will be effective through the end of 2029, while certain economic terms may be renegotiated by the parties following the lapse of the first four years of the term of the agreement.

See the original post:
Kamada Announces Resolution to the Labor Strike at the Company’s Manufacturing Facility in Israel; A New, Eight-Year Collective Agreement Signed

Read More...

BioCryst to Present at Upcoming Investor Conference

July 17th, 2022 1:46 am

RESEARCH TRIANGLE PARK, N.C., July 15, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the H.C. Wainwright 1st Annual Hereditary Angioedema Virtual Conference on Wednesday, July 20, 2022, at 10:00 a.m. ET.

Continue reading here:
BioCryst to Present at Upcoming Investor Conference

Read More...

SIGA Announces Oncology Collaboration with KaliVir Immunotherapeutics

July 17th, 2022 1:46 am

SIGA to Supply TPOXX® to Support KaliVir’s Oncolytic Vaccinia Clinical Immunotherapy Program SIGA to Supply TPOXX® to Support KaliVir’s Oncolytic Vaccinia Clinical Immunotherapy Program

Original post:
SIGA Announces Oncology Collaboration with KaliVir Immunotherapeutics

Read More...

Synthetic Biologics Announces Reverse Stock Split

July 17th, 2022 1:46 am

ROCKVILLE, Md., July 15, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, announced today a reverse stock split of its issued and outstanding common stock, par value $0.001 per share, at a ratio of one (1) share of common stock for every ten (10) shares of common stock, effective as of 12:01 a.m. (Eastern Time) on July 25, 2022 (the “Effective Date”). The Company’s common stock will begin trading on a split-adjusted basis when the market opens on July 25, 2022. The reverse stock split was authorized by the Company’s Board of Directors on July 11, 2022. Pursuant to the laws of the State of Nevada, the Company’s state of incorporation, the Company’s Board of Directors has the authority to effect a reverse stock split without shareholder approval if the number of authorized shares of common stock and the number of outstanding shares of common stock are proportionally reduced. The Company will file a certificate of change to its articles of incorporation, as amended, with the Secretary of State of Nevada to effect the reverse stock split. The Company’s common stock will continue to trade on the NYSE American under the stock ticker “SYN” but will trade under the new CUSIP number 87164U409.

Read more from the original source:
Synthetic Biologics Announces Reverse Stock Split

Read More...

Marijuana Strategic Ventures, Inc. (OTC: MSVI) Announces Updates for Mushrooms, Inc., Health Product Production, Provisional Patent and Business Plan…

July 17th, 2022 1:46 am

ESTERO, Fla., July 15, 2022 (GLOBE NEWSWIRE) -- Marijuana Strategic Ventures, Inc. (the “Company”) (OTC: MSVI) announces updates to the progress of its three areas of focus: Health, Innovation and Research & Development.

Continue reading here:
Marijuana Strategic Ventures, Inc. (OTC: MSVI) Announces Updates for Mushrooms, Inc., Health Product Production, Provisional Patent and Business Plan...

Read More...

CENTOGENE Reports First Quarter 2022 Financial Results

July 17th, 2022 1:46 am

On Track for FY 2022 Guidance

Link:
CENTOGENE Reports First Quarter 2022 Financial Results

Read More...

Quoin Pharmaceuticals and Endo Ventures Limited Enter Into Exclusive Distribution and Supply Agreements

July 17th, 2022 1:46 am

Endo affiliate, Paladin Labs, will commercialize Quoin’s lead asset for Netherton Syndrome in Canada Endo affiliate, Paladin Labs, will commercialize Quoin’s lead asset for Netherton Syndrome in Canada

Go here to read the rest:
Quoin Pharmaceuticals and Endo Ventures Limited Enter Into Exclusive Distribution and Supply Agreements

Read More...

Page 153«..1020..152153154155..160170..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick